xm:段文虎
xb:男
zc:研究员
xl:博士
dh:+86-
cz:
dzyj:whduan@simm.ac.cn
grzy:
zjlb:研究员
zw:研究组长、博士生导师、化学药物研发中心主任
txdz:上海市祖冲之路555号
grjj:段文虎，1986年毕业于中国药科大学，获理学学士学位；1993年毕业于华西医科大学药学院，获理学硕士学位；1996年毕业于中国科学院上海药物研究所，获理学博士学位。1997年至2000年先后在美国伦塞勒工学院、德州大学奥斯汀分校等大学从事博士后研究。现任中国科学院上海药物研究所研究员、课题组长。目前已发表学术论文100余篇。申请专利30多项，其中已授权11项。“已获候选新药3个，其中1个已申报新药临床研究”专业：药物化学

教育经历

1982.09-1986.06 中国药科大学 本科

1990.09-1993.06 华西医科大学（现四川大学华西医学中心） 硕士

1993.09-1996.06 中国科学院上海药物研究所 博士

yjfx:本课题组从事抗肿瘤药物的设计和合成研究，旨在研发抗肿瘤新药，主要研究方向

1.靶点抗肿瘤药物的研究开发，针对与肿瘤发生、生长、转移密切相关的靶酶/蛋白，结合合理药物设计和经典药物设计方法，研究发现新型高效低毒抗肿瘤候选药物。主要研究的靶点包括VEGFR、STING、AXL、IRAK4、PRMT、PRC2、c-Met、FGFR等。

2.开展一些具有抗肿瘤活性天然产物的合成及结构修饰工作，旨在以活性天然产物为先导物，发现具有独特作用机制的抗肿瘤候选药物。

dblz:1. Jingwei Shao, Kongkai Zhu, Daohai Du, Yuanyuan Zhang, Hongrui Tao, Zhifeng Chen, Hualiang Jiang, Kaixian Chen, Cheng Luo*, Wenhu Duan*. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2019, 164(15):317-333.

2. Kongkai Zhu, Jingwei Shao, Hongrui Tao, Xue Yan, Cheng Luo, Hua Zhang*, Wenhu Duan*. Rational design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Journal of Computer-Aided Molecular Design, 2019, 33(8): 775-785.

3. Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai*, and Wenhu Duan*. Discovery of potent irreversible pan-fibroblast growth factor receptor (FGFR) inhibitors. Journal of Medicinal Chemistry, 2018, 61(20): 9085-9104.

4. Zhengsheng Zhan, Xia Peng, Yiming Sun, Jing Ai*, and Wenhu Duan*. Evaluation of deuterium-labeled JNJ**: pharmacokinetic, metabolic, and in vivo antitumor profiles. Chemical Research in Toxicology, 2018, 31(11): 1213-1218.

5. Ruifeng Mao, Jingwei Shao, Kongkai Zhu, Yuanyuan Zhang, Hong Ding, Chenhua Zhang, Zhe Shi, Hualiang Jiang, Dequn Sun*, Wenhu Duan*, and Cheng Luo*. Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization. Journal of Medicinal Chemistry, 2017, 60(14): 6289-6304.

6. Zhengyu Wang, Xiaofan Shi, Huan Zhang, Liang Yu, Yanhua Cheng, Hefeng Zhang, Huibin Zhang, Jinpei Zhou*, Jing Chen*, Xu Shen, and Wenhu Duan*. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2017, 139: 128-152.

7. Wei Yan, Xinyi Wang, Yang Dai, Bin Zhao, Xinying Yang, Jun Fan, Yinglei Gao, Fanwang Meng, Yuming Wang, Chen Luo, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of 3-(5\'-substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation. Journal of Medicinal Chemistry, 2016, 59(14): 6690-6708.

8. Bin Zhao, Yixuan Li, Pan Xu, Yang Dai, Cheng Luo, Yiming Sun, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of substituted 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors. ACS Medicinal Chemistry Letters, 2016, 7(6): 629-634.

9. Jun Fan, Yang Dai, Jingwei Shao, Xia Peng, Chen Wang, Sufen Cao, Bin Zhao,Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorganic & Medicinal Chemistry Letters, 2016, 26 (11): 2594-2599.

10. Zhengsheng Zhan, Xia Peng, Qiufeng Liu, Fang Chen, Yinchun Ji, Shanyan Yao, Yong Xi, Yipeng Lin, Tiantian Chen, Yechun Xu*, Jing Ai*, Meiyu Geng*, and Wenhu Duan*. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b] [1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. European Journal of Medicinal Chemistry, 2016, 116: 239-251.

11. Wei Yan, Zhaoru Huang, Zhengyu Wang, Sufen Cao, Linjiang Tong, Tao Zhang, Chen Wang, Lin Zhou, Jian Ding, Cheng Luo*, Jinpei Zhou*, Hua Xie*, and Wenhu Duan*. Discovery of 1,3-diaryl-pyridones as potent VEGFR-2 inhibitors: design, synthesis, and biological evaluation. Chemical Biology & Drug Design, 2016, 87(5): 694-703.

12. Mengyuan Li, Yongcong Lv, Linjiang Tong, Ting Peng, Rong Qu, Tao Zhang, Yiming Sun, Yi Chen, Lixin Wei, Meiyu Geng, Wenhu Duan*, Hua Xie*, and Jian Ding*. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacologica Sinica, 2016, 37 (3): 398-407.

13. Guorui Gao, Mengyuan Li, Yongcong Lv, Sufen Cao, Linjiang Tong, Lixin Wei, Jian Ding, Hua Xie, and Wenhu Duan*. Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II). Chinese Chemical Letters, 2016, 27(2): 200-204.

14. Guorui Gao, Mengyuan Li, Linjiang Tong, Lixin Wei, Jian Ding*, Hua Xie*, and Wenhu Duan*. Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I). Chinese Chemical Letters, 2015, 26(9): 1165-1168.

15. Yongcong Lv, Mengyuan Li, Sufen Cao, Linjiang Tong, Ting Peng, Lixin Wei, Hua Xie*, Jian Ding*, and Wenhu Duan*. Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. MedChemComm, 2015, 6(7): 1375-1380.

16. Yanyan Sun, Jun Fan, Zhiyuan Zhu*, Xiaodan Guo, Tingting Zhou, Wenhu Duan*, and Xu Shen*. Small molecule TBTC as a new selective retinoid X receptor α agonist improves behavioral deficit in alzheimer\'s disease model mice. European Journal of Pharmacology, 2015, 762: 202-213.

17. Jianrui Wu, Ting Peng, Fang Chen, Yixin Leng , Linjiang Tong, Mengyuan Li, Rong Qu , Hua Xie*, Jian Ding*, and Wenhu Duan*. Synthesis and anticancer activity of 7,8-dihydroxy-4-arylcoumarins. Letters in Drug Design & Discovery, 2015, 12(5): 366-73.

18. Guorui Gao, Jiali Liu, Desheng Mei, Jian Ding, Linghua Meng*, and Wenhu Duan*. Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors. Chinese Chemical Letters, 2015, 26 (1): 118-120.

19. Ting Peng, Jianrui Wu, Linjiang Tong, Mengyuan Li, Fang Chen, Yixin Leng, Rong Qu, Kun Han, Yi Su, Yi Chen, Wenhu Duan*, Hua Xie*, and Jian Ding*. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin. Acta Pharmacologica Sinica, 2014, 35(7): 916-928.

20. Zhengsheng Zhan, Jing Ai, Qiufeng Liu, Yinchun Ji, Tiantian Chen, Yechun Xu*, Meiyu Geng*, and Wenhu Duan*. Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: synthesis, SAR, and cellular activity. ACS Medicinal Chemistry Letters, 2014, 5(6): 673-678.

21. Yongcong Lv, Mengyuan Li, Ting Liu, Linjiang Tong, Ting Peng, Lixin Wei, Jian Ding, Hua Xie*, and Wenhu Duan*. Discoverr of a new series of naphthamides as potent VEGFR-2 kinase inhibitors. ACS Medicinal Chemistry Letters, 2014, 5(5): 592-597.

jyjl:1982.09-1986.06中国药科大学 本科